Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
CE

NASDAQ · CEROW

CERo Therapeutics Holdings, Inc.

Healthcare · Biotechnology

$0.00

Up+$0.00 (+0.00%)

Updated Nov 5, 2026, 7:43 AM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
158.75K
P/E ratio
-0.01
Dividend yield
0.00%
52-week range
— – —
Volume
100K
Avg. volume
114.57K

Price performance · CEROW

CEROW price history

1M range · 0 trading sessions · Daily adjusted prices

CEROW does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest CEROW news

The latest Smart Investors Daily articles mentioning CEROW.

Stock researchCompany · Overview

CEROW research

Overview

Company profile and research snapshot.

Company profile

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms, today announced that the University of California, Davis (UC Davis), has been activated as a clinical trial site for CERTAIN-T, the Company's ongoing Phase 1 study evaluating CER-1236 in patients with hematologic malignancies. UC Davis

Yahoo · Oct 26, 2026

SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline treatment logistics Update follows SRX’s previously announced definitive agreement to acquire CERo Therapeutics NORTH PALM BEACH, Fla., Oct. 26, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating com

Yahoo · Oct 26, 2026

CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers

SOUTH SAN FRANCISCO, Calif, Oct. 26, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms, announces that Fred Hutch Cancer Center (“Fred Hutch”) in Seattle, Wash., has been activated as a clinical trial site for the Company’s Phase 1 clinical trial of CER-1236, CERTAIN-T. Jacob Appelbaum, M.D., Ph.D., Assistant Professor, D

Yahoo · Oct 7, 2026

SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies

SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders Proposed acquisition expected to accelerate development of CERo's lead product candidate, CER-1236, for hematologic malignancies NORTH PALM BEACH, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strat

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By